Artisan Small Cap Fund Sold Insmed (INSM) on Valuation Consideration

Group 1 - Artisan Small Cap Fund aims to invest in companies with franchise characteristics, strong earnings trajectories, and trading at a discount to estimated private market value [1] - In Q4 2025, the Fund posted strong absolute returns, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index, despite elevated volatility and shifting market sentiment [1] - For the full year 2025, the Fund generated strong results but underperformed compared to both indexes [1] Group 2 - Insmed Incorporated (NASDAQ:INSM) was highlighted as a leading contributor in Q4 2025, focusing on therapies for serious and rare diseases [2][3] - As of March 16, 2026, Insmed's stock closed at $144.60 per share, with a one-month return of -3.93% and a 52-week gain of 87.82% [2] - Insmed's market capitalization is reported at $31.17 billion [2] - The company launched Brinsupri™ (brensocatib), generating $28 million in initial sales from approximately 2,500 patients and 1,700 prescribers, contributing to its strong performance [3]